November 19, 2020

19 Nov 20 | US, EU | Alvotech | Alvotech announces the FDA and EMA have accepted its regulatory submissions for AVT02 (proposed adalimumab biosimilar). Approval is expected in the US in September 2021 and Q4 2021 in the EU.

04 Nov 20 | CA | Amgen | Amgen receives three...

Please reload

Biosimilars bulletin 

November 9, 2020

Please reload

Search by tags